CPN1 and Huntington disease: While these data suggest that inactivation of wild-type and mutant HTT in SPN and CPN could be considered in patients with Huntington's disease, we cannot exclude the possibility that species-specific differences in life expectancy, brain structures/functions and the presence of mutant HTT in patients with Huntington's disease may alter the outcome of HTT inactivation.